TENBORON LTDNovel boron carriers for Boron Neutron Capture Therapy
BNCT is biochemically targeted radiation therapy. Boron-10 (10B) atoms are selectively delivered to the tumor, followed by irradiation with epithermal neutrons (nth). A nuclear reaction occurs, when a 10B atom captures a neutron. The short range of the reaction products restricts most of the radiation dose to the boron-loaded cells.
The stable boron isotope 10B has a large neutron capture radius. Thus 10B is more likely to capture neutrons than many other elements that are present in biological environments (e.g. nitrogen and hydrogen). A fission reaction occurs upon neutron capture, and a lithium ion and an alpha particle are produced. These particles have high kinetic energies, but their range is only about 10 microns. This leads to very efficient cancer cell killing precisely at the site of boron accumulation.
Has been in previous studies curative for 15-20% of terminal phase patients, despite using sub-optimal boron carrier
Can be used to treat many kinds of solid tumors that can be boron loaded
Affects healthy tissues less than conventional radiation therapy
Can be used in combination with other treatments
Low number of treatment sessions
Short hospital period – outpatient in many cases
Can be repeated
Boron Neutron Capture reaction leads to intense local irradiation precisely at the site of boron accumulation, which leads to tumor necrosis
Dr. Timo Veromaa,
Dr. Anu Muona,
Mr. Juhani Saarinen,
Dr. Seppo Pakkala,
Board Member and Chief Medical Officer
Mr. Juha Jouhki,
Chief Executive Officer
Partner: Glykos Finland Ltd.
Dr. Jari Helin,
Head of CMC
Dr. Jukka Hiltunen,
Ms. Sirkku Holttinen,
Quality Assurance Manager
Partners: Biovian Ltd.
and Medfiles Ltd.
Partner: Optimapharm Ltd.